arrow
A

Ann Marie Návar

ut southwestern medical center
H指数:50
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Global prevalence of elevated high-sensitivity C-reactive protein in patients with atherosclerotic cardiovascular disease, with and without chronic kidney disease: findings from the POSEIDON study

全球动脉粥样硬化性心血管疾病患者中高敏C反应蛋白升高的患病率:伴有与不伴有慢性肾脏病的比较——POSEIDON研究的结果

2026-06-180
PRE
Association of Lp(a) With Cardiovascular Disease and All-Cause Mortality in U.S. Hispanics and Latinos

Lp(a)与美籍西班牙裔和拉丁裔人群中心血管疾病及全因死亡率的相关性

JACC
IF0
2025-12-010
PRE
Management Patterns and Outcomes of Invasive Mechanical Ventilation in Patients With Cardiogenic Shock

心源性休克患者侵入性机械通气的管理模式和结局

2025-10-011
OAAI
Factors associated with elevated high-sensitivity C-reactive protein levels in individuals with atherosclerotic cardiovascular disease in the USA and the UK

与美英两国动脉粥样硬化性心血管疾病患者高敏C反应蛋白水平升高相关的因素

2025-10-011
OAAI
2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement)

2025年AHA/ACC关于临床实践指南中成本/价值方法学的声明(2014年声明的更新)

JACC
IF0
2025-09-250
PRE
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics

RATIONALE AND DESIGN OF THE REMBRANDT TRIAL: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics: REMBRANDT试验的原理与设计:一项评估obicetrapib/ezetimibe对冠状动脉斑块特征影响作用的III期研究

2025-07-170
OAAI
SBDH-Reader: a large language model-powered method for extracting social and behavioral determinants of health from clinical notes

SBDH-Reader:一种基于大型语言模型的方法,用于从临床记录中提取健康的社会和行为决定因素

2025-07-012
OAAI
LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: VICTORION-INCEPTION

使用英克利希兰联合常规护理与单独常规护理管理近期急性冠脉综合征患者的LDL-C:VICTORION-INCEPTION

2025-05-290
PRE
Effect of Obicetrapib on New Onset Diabetes In Patients with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the Broadway and Brooklyn Trials

Obicetrapib对接受最大耐受剂量他汀类药物治疗的LDL-C升高患者中新发糖尿病的影响:Broadway和Brooklyn试验的合并分析

2025-05-290
PRE
Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial

塞马格鲁肽2.4 mg在肥胖或超重并伴有心血管疾病患者中的群体水平影响:一项基于SELECT试验的建模研究

2025-04-040
OA